Malignant mesothelioma: Options for management

Surgical Clinics of North America

Volumn 82, Issue 4, 2002, Pages 797-831

  Singhal, Sunil ^a   Kaiser, Larry R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG RESECTION; MALIGNANT MESOTHELIOMA; PHOTODYNAMIC THERAPY; PLEURECTOMY; PRIORITY JOURNAL; REVIEW;

HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM STAGING; PALLIATIVE CARE;

EID: 0036703815     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00033-6     Document Type: Review

References (189)

1. Butchart EG. Contemporary management of malignant pleural mesothelioma. Oncologist 1999;4:488-500.
2. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
3. Falkson G, Alberts AS, Falkson HC. Malignant pleural mesothelioma treatment: The current state of the art. Cancer Treat Rev 1988;15:231-42.
4. Harvey JC, Erdman C, Pisch J, et al. Diffuse malignant pleural mesothelioma: Options in surgical treatment. Compr Ther 1995;21:13-9.
5. Huncharek M, Kelsey K, Mark EJ, et al. Treatment and survival in diffuse malignant pleural mesothelioma: A study of 83 cases from the Massachusetts General Hospital. Anticancer Res 1996;16:1265-8.
6. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1-2.
7. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-25 [discussion 825-6].
8. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981;8:313-20.
9. Brenner J, Sordillo PP, Magill GB, et al. Malignant mesothelioma of the pleura: Review of 123 patients. Cancer 1982;49:2431-5.
10. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982;96:746-55.
11. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988;93:159-62.
12. Harvey JC, Fleischman EH, Kagan AR, et al. Malignant pleural mesothelioma: A survival study. J Surg Oncol 1990;45:40-2.
13. Law MR, Hodson ME, Turner-Warwick M. Malignant mesothelioma of the pleura: Clinical aspects and symptomatic treatment. Eur J Respir Dis 1984;65:162-8.
14. Ruffle P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
15. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
16. Sugarbaker DJ, Mentzer SJ, DeCamp M, et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 1993;103:377S-81S.
17. Rusch VW. Indications for pneumonectomy. Extrapleural pneumonectomy. Chest Surg Clin North Am 1999;9:327-38.
18. Moreno de la Santa P. Butchart EG: Therapeutic options in malignant mesothelioma. Curr Opin Oncol 1995;7:134-7.
19. Conlon KC, Rusch VW, Gillern S. Laparoscopy: An important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol 1996;3:489-94.
20. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991;28:319-30.
21. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996;14:1007-17.
22. Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:361-6.
23. British Thoracic Society Standards of Care C. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56:250-65.
24. Steele JP, Rudd RM. Malignant mesothelioma: Predictors of prognosis and clinical trials. Thorax 2000;55:725-6.
25. Ollikainen T, Knuuttila A, Suhonen S, et al. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs 2000;11:93-9.
26. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-65.
27. Kindler HL, Millard F, Herndon 2nd JE, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-7.
28. Krarup-Hansen A. Phase II trials of malignant mesothelioma: A commentary and update [comment]. Lung Cancer 1994;11:305-8.
29. Krarup-Hansen A. Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma. Lung Cancer 1996;16:101-2.
30. Krarup-Hansen A. Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma [letter]. Lung Cancer 1996;16:101-2.
31. Maksymiuk AW, Marschke Jr RF, Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998;21:610-3.
32. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992;10:824-8.
33. Mbidde EK, Harland SJ, Calvert AH, et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986;18:284-5.
34. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000;18:243-5.
35. Palackdharry CS. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Semin Oncol 1997;24:(S2)108-12.
36. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8:151-4.
37. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992;65:956-60.
38. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16.
39. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239-42.
40. Vogelzang NJ, Weissman LB, Herndon JEn, et al. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 1994;12:1436-42.
41. Zidar BL, Metch B, Balcerzak SP, et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group. Cancer 1992;70:2547-51.
42. Fizazi K, Caliandro R, Soulie P, et al. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 2000;36:1514-21.
43. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984;54:961-4.
44. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983;52:1981-5.
45. Rossof AH. Treatment II, chemotherapy in the management of malignant mesothelioma. In: Kittle CF, editor Mesothelioma: Diagnosis and Management. Chicago: Year Book Medical Publishers; 1987. p. 73-8.
46. Vogelzang NJ, Schultz SM, Iannucci AM, et al. Malignant mesothelioma. The University of Minnesota experience. Cancer 1984;53:377-83.
47. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999;17:25-30.
48. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995;6:613-5.
49. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9:1315-22.
50. Shukunami K, Hirabuki S, Kaneshima M, et al. Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: Successful treatment by local and systemic administration of carboplatin. Tumori 2000;86:419-21.
51. Thodtmann R, Depenbrock H, Blatter J, et al. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. Semin Oncol 1999;26:89-93.
52. Vogelzang NJ, Herndon 2nd JE, Miller A, et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999;10:597-600.
53. White SC, Anderson H, Jayson GC, et al. Randomised phase II study of cisplatinetoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol 2000;11:201-6.
54. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-7.
55. Hunt KJ, Longton G, Williams MA, et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239-42.
56. Hoffman K. Paclitaxel and carboplatin combination chemotherapy is an effective palliative treatment for malignant mesothelioma. Proc Annu Meet Am Soc Clin Oncol 1996;15:A1428.
57. Chahinian AP, Mandeli JP, Gluck H, et al. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 1998;67:104-11.
58. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma - A negative report. Cancer Chemother Pharmacol 1989;24:133-4.
59. Palackdharry CS. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: Preliminary results. Semin Oncol 1996;23:78-83.
60. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74:961-3.
61. Magri MD, Foladore S, Veronesi A, et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II cooperative study. Ann Oncol 1992;3:237-8.
62. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987;71:857-8.
63. Anand A, Anand N. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1996;77:1959-60.
64. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 1991;67:2984-7.
65. Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials. Eur J Cancer 1999;35:S14-8.
66. Baas P, van Meerbeeck J, Groen H, et al. Caelyx in malignant mesothelioma: A phase II EORTC study. Ann Oncol 2000;11:697-700.
67. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994;5:653-5.
68. Gridelli C, Pepe R, Airoma G, et al. Mitomycin C and vindesine: An ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 1992; 78:380-2.
69. Hasturk S, Tastepe I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996;8:159-64.
70. Nakano T, Chahinian AP, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999;85:2375-84.
71. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 1997;79:1897-902.
72. Pinto C, Marino A, Guaraldi M, et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol 2001;24:143-7.
73. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments]. Cancer 1995;76: 2230-6.
74. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma [see comments]. Lung Cancer 1994;11:299-303.
75. Tsavaris N, Primikirios N, Mylonakis N, et al. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective]. Anticancer Res 1997;17:3799-802.
76. Kindler HL, Belani CP, Herndon 2nd JE, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999;86:1985-91.
77. Samuels BL, Herndon 2nd JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Cancer 1998;82:1578-84.
78. Vogelzang NJ, Herndon 2nd JE, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997;79:2237-42.
79. Colleoni M, Sartori F, Calabro F, et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996;82:53-6.
80. Figlin R, Mendoza E, Piantadosi S, et al. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest 1994;106:363S-6S.
81. Lerza R, Esposito M, Vannozzi M, et al. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses. Cancer 1994;73:79-84.
82. Sauter ER, Langer C, Coia LR, et al. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995;60:100-5.
83. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.
84. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994;38:212-4.
85. Reddy S. Treatment III: Radiation in the therapy of malignant mesothelioma. In: Kittle CF, editor. Mesothelioma: Diagnosis and Management. Chicago: Year Book Medical Publishers; 1987. p. 79-86.
86. Mattson K, Holsti LR, Tammilehto L, et al. Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. Int J Radiat Oncol Biol Phys 1992;24:643-50.
87. de Graaf-Strukowska L, van der Zee J, van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511-6.
88. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol 1991;3:315-7.
89. Kittle CF. Treatment I: The surgical treatment of mesothelioma. In: Kittle CF, editor. Mesothelioma: Diagnosis and Management. Chicago: Year Book Medical Publishers; 1987. p. 61-72.
90. Vogelzang NJ. Malignant mesothelioma: Diagnostic and management strategies for 1992. Semin Oncol 1992;19:64-71.
91. Patz Jr EF, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability. Am J Roentgenol 1992;159:961-6.
92. Pass HI, Pogrebniak HW. Malignant pleural mesothelioma. Curr Probl Surg 1993; 30:921-1012.
93. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:367-72.
94. Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001;31:57-65.
95. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995;107: 332S-44S.
96. Brancatisano RP, Joseph MG, McCaughan BC. Pleurectomy for mesothelioma [see comments]. Med J Aust 1991;154:455-7,460.
97. Takahashi K, Yoshida J, Nishimura M, et al. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases? Jpn J Thorac Cardiovasc Surg 2001;49:89-93.
98. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996;224:288-94 [discussion: 294-6].
99. Aisner J. Therapeutic approach to malignant mesothelioma. Chest 1989;96:95S-7S.
100. Kittle CF. Mesothelioma: Diagnosis and Management. Chicago: Year Book Medical Publishers; 1987.
101. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol 1997;4:215-22.
102. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat Res 2001;105:327-73.
103. Keller SM. Adjuvant therapy for malignant pleural mesothelioma. Chest Surg Clin N Am 1994;4:127-35.
104. Lampl L, Jakob R. How should we treat malignant pleural mesothelioma (MPM)? Acta Chir Hung 1999;38:87-90.
105. Liu CC, Hsu WH, Li WY, et al. Treatment results of 17 patients with diffuse pleural mesothelioma. Ann Thorac Cardiovasc Surg 1998;4:233-9.
106. Moskal TL, Urschel JD, Anderson TM, et al. Malignant pleural mesothelioma: A problematic review. Surg Oncol 1998;7:5-12.
107. Ruffle P, Lehmann M, Galateau-Salle F, et al. Malignant mesothelioma. Br J Cancer 2001;84:49-50.
108. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: Who benefits? Chest 1995;107:345S-50S.
109. Linden CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: A nonrandomized phase II study. Eur Respir J 1996;9:2565-72.
110. Sinoff C, Falkson G, Sandison AG, et al. Combined doxorubicin and radiation therapy in malignant pleural mesothelioma. Cancer Treat Rep 1982;66:1605-7.
111. Allen KB, Faber LP, Warren WH. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am 1994;4:113-26.
112. Faber LP. Surgical treatment of asbestos-related disease of the chest. Surg Clin North Am 1988;68:525-43.
113. Faber LP. 1986: Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Updated in 1994. Ann Thorac Surg 1994;58:1782-3.
114. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994;12:1156-63.
115. Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group trial. J Clin Oncol 1991;9:313-9.
116. Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999;116:450S-4S.
117. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63 [discussion: 63-5].
118. Sugarbaker DJ, Garcia JP. Multimodality therapy for malignant pleural mesothelioma. Chest 1997c;112:272S-5S.
119. Sugarbaker DJ, Norberto JJ, Swanson SJ. Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:373-82.
120. Sugarbaker DJ, Richards WG, Garcia JP. Extrapleural pneumonectomy for malignant mesothelioma. Adv Surg 1997;31:253-71.
121. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-8.
122. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma [see comments]. J Thorac Cardiovasc Surg 1991;102:10-14 [discussion: 14-15].
123. Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr 1988; 66:607-13.
124. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 1993;103:382S-4S.
125. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-804.
126. Hilaris BS, Nori D, Kwong E, et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 1984;10:325-31.
127. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg 1987;43:113-20.
128. Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol 1997;66:19-23.
129. Lee JD, Perez S, Wang HJ, et al. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The UCLA experience. J Surg Oncol 1995;60:262-7.
130. Rusch VW. Trials in malignant mesothelioma. LCSG 851 and 882. Chest 1994;106: 359S-62S.
131. Kaiser LR, Albelda SM. Gene transfer and thoracic surgery: More to come. Ann Thorac Surg 1997;63:1527-8.
132. Schwarzenberger P, Byrne P, Kolls JK. Immunotherapy-based treatment strategies for malignant mesothelioma. Curr Opin Mol Ther 1999;1:104-11.
133. Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study. Aust N Z J Med 1993;23:683-7.
134. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 2001;31: 303-10.
135. Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998;21:389-98.
136. Fitzpatrick DR, Manning LS, Musk AW, et al. Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 1995;21:273-88.
137. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995;12:455-60.
138. Mulatero CW, Penson RT, Papamichael D, et al. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 2001;31:67-72.
139. O'Reilly EM, Ilson DH, Saltz LB, et al. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999;17:195-200.
140. Purohit A, Moreau L, Dietemann A, et al. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 1998;22: 119-25.
141. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I - II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996;14:878-85.
142. Tansan S, Emri S, Selcuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994;51:348-51.
143. Nano R, Capelli E, Civallero M, et al. Effects of interleukin-2 for the treatment of malignant mesothelioma. Oncol Rep 1998;5:489-92.
144. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer 1998;83:2099-104.
145. Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: A multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998;84:558-61.
146. Duensing S, Hamm H, Ganser A, et al. Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesothelioma. Cancer Biother Radiopharm 1997;12:141-2.
147. Karrison TG, Vogelzang NJ. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer 1999;86:546-7.
148. Krastev Z, Koltchakov V, Vladov N, et al. A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 2001;50:226-7.
149. Astoul P, Bertault-Peres P, Durand A, et al. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer 1994;73:308-13.
150. Astoul P, Viallat JR, Laurent JC, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103:209-13.
151. Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I - II study. Br J Cancer 1995;72:1283-8.
152. Fizazi K, Ducreux M, Ruffie P, et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000;18:2293-300.
153. McLaren BR, Robinson BW, Lake RA. New chemotherapeutics in malignant mesothelioma: Effects on cell growth and IL-6 production. Cancer Chemother Pharmacol 2000;45:502-8.
154. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853-7.
155. Stam TC, Swaak AJ, Kruit WH, et al. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: Cytokine patterns and acute-phase protein response. Eur J Clin Invest 2000;30:336-43.
156. Trandafir L, Ruffle P, Borel C, et al. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997;33:1900-2.
157. Metintas M, Ozdemir N, Ucgun I, et al. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 1999;116:391-8.
158. Takagi K, Fukushima Y, Kanou J, et al. A long-term survivor case of malignant mesothelioma treated by recombinant tumor necrosis factor-SAM2 (TNF-alpha mutein) and 5-fluorouracil (5-FU): A new therapeutic approach based on host-tumor relationship. Anticancer Res 1998;18:4591-600.
159. Temeck BK, Pass HI. Esophagopleural fistula: A complication of photodynamic therapy. South Med J 1995;88:271-4.
160. Vogelzang NJ. Gemcitabine and cisplatin: Second-line chemotherapy for malignant mesothelioma [letter; comment]? J Clin Oncol 1999;17:2626-7.
161. Galen WP. Hyperthermia and chemotherapy. Adv Exp Med Biol 1990;267:209-16.
162. Miller RC, Richards M, Baird C, et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994;10:89-99.
163. Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989; 27:621-7.
164. Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999;117:759-65.
165. Carry PY, Brachet A, Gilly FN, et al. A new device for the treatment of pleural malignancies: Intrapleural chemohyperthermia preliminary report. Oncology 1993;50:348-52.
166. Coulon L, Bienvenu J, Gutowski MC, et al. Cytokine production during intraperitoneal chemohyperthermia. Oncology 1993;50:371-4.
167. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16.
168. Smythe WR, Kaiser LR, Hwang HC, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57: 1395-401.
169. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998;9:2121-33.
170. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-92.
171. Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511-8.
172. Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study. Hum Gene Ther 1998;9:2641-9.
173. Schwarzenberger P, Harrison L, Weinacker A, et al. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998;150:168-74.
174. Chmura SJ, Advani SJ, Kufe DW, et al. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig 1999;7:261-9.
175. Wildner O, Blaese RM, Morris JC. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum Gene Ther 1999;10:2679-87.
176. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999;10:3013-29.
177. Printz MA, Gonzalez AM, Cunningham M, et al. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 2000;11:191-204.
178. Baas P, Murrer L, Zoetmulder FA, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997;76:819-26.
179. Ris HB, Altermatt HJ, Nachbur B, et al. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med 1996;18:39-45.
180. Schouwink H, Ruevekamp M, Oppelaar H, et al. Photodynamic therapy for malignant mesothelioma: Preclinical studies for optimization of treatment protocols. Photochem Photobiol 2001;73:410-7.
181. Luketich JD, Westkaemper J, Sommers KE, et al. Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Ann Thorac Surg 1996;62:283-4.
182. Takita H, Mang TS, Loewen GM, et al. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: A phase II study. Ann Thorac Surg 1994;58:995-8.
183. Moskal TL, Dougherty TJ, Urschel JD, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998;66:1128-33.
184. Ris HB, Giger A, Hof VI, et al. Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma. Eur J
185. Selikoff IJ, Lee DHK. Asbestos and Disease. New York: Academic Press; 1978.
186. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993;105:743-7 [discussion: 747-81.
187. Senyigit A, Bayram H, Babayigit C, et al. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: A review of 117 cases. Respiration 2000;67:623-9.
188. Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996;110:1387-93.
189. Jackson MB, Pounder D, Price C, et al. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax 1999;54:238-41.